Korsana Biosciences vs Seres Therapeutics
Korsana Biosciences is the larger business, with $2.1m of revenue in fiscal 2025 against $789,000 for Seres Therapeutics (2.6 times as much). Seres Therapeutics kept more of each dollar of sales as profit: a net margin of 721.9% against -170.1%.
| Latest fiscal year | Korsana BiosciencesKRSA, 2025 | Seres TherapeuticsMCRB, 2025 |
|---|---|---|
| Revenue | $2.1m | $789,000 |
| Revenue growth | 3.7% | — |
| Net income | −$3.5m | $5.7m |
| Operating margin | -239.8% | — |
| Net margin | -170.1% | 721.9% |
| Return on equity | -39.3% | 19.6% |
| Free cash flow | −$3.3m | $865,000 |
| Cash | $3.2m | $45.8m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 66 |
| Market value | $138m | $18.9m |
| Price vs our value range | — | Below our value range |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 16 sales |